Abstract

Mass spectrometry imaging (MSI) technology has emerged as a transformative tool in drug toxicity assessment, revolutionizing the way pharmaceuticals are evaluated for safety and efficacy. MSI allows for the spatial visualization and simultaneous identification of drug distribution and metabolites within biological tissues, providing unprecedented insights into drug toxicity mechanisms. This article explores the application of MSI technology in drug toxicity assessment and its impact on drug development, early detection of toxic metabolites, personalized medicine, and preclinical safety assessment. By facilitating the understanding of drug-tissue interactions at a cellular level, MSI holds the potential to optimize drug development processes, enhance drug safety, and pave the way for a new era of personalized medicine. This article explores the application of MSI in drug toxicity assessment, highlighting its impact on spatial drug distribution analysis, early detection of toxic metabolites, mechanistic understanding of toxicity, personalized medicine, and preclinical safety assessment. With MSI’s potential to optimize drug development, enhance safety profiles, and advance personalized therapeutic approaches, this technology represents a breakthrough in the pursuit of safer and more effective medications.